JPH02110A - Solid iodophor preparation - Google Patents

Abstract

PURPOSE:To obtain the title simply producible preparation having excellent stability, evolving iodine by rapidly dissolving in water, showing excellently germicidal power containing an iodine carrier, iodide, oxidizing agent and powder acid in a specific state. CONSTITUTION:A solid iodophor preparation containing (A) an iodine carrier, preferably surfactant or water-soluble saccharide, (B) an iodide, preferably alkali metal iodide, (C) an oxidizing agent such as chloric acid (chlorate), chromic acid (chromate) or halogenated isocyanuric acid (isocyanurate), (D) a powder acid such as saturated dicarboxylic acid, oxyacid or inorganic acid and, if necessary, (E) a powder salt which is reacted with the component D and expanded wherein one component of the components B-D is separately formed from the other two components. Contents of the components are preferably 5-50wt.% component A, 0.1-10wt.% component B, 0.1-10wt.% component C, 10-70wt.% component D and 5-40wt.% component E.

Description

[Detailed description of the invention] [Industrial application field] The present invention relates to solid iodophor formulations.

[Prior Art] Conventionally, as a solid iodophor preparation, there is one in which iodine is mechanically blended into a solid solution consisting of polyvinylpyrrolidone and iodide to form a complex (for example, JP-A-50
-35318).

[Problems to be Solved by the Invention] However, the production of this product requires complicated steps, and there is also the problem that iodine sublimes from the solid iodophor.

[Means for Solving the Problems] The present inventors have conducted intensive studies to find a stable solid iodophor preparation that is easy to produce, and as a result, they have arrived at the present invention.

That is, the present invention includes: iodine carrier (a), iodide (b)
, oxidizing agent (c), powdered acid (d) and optionally (d)
It contains powdered base (e) which has the property of foaming when reacting with
This is a solid iodophor preparation (hereinafter referred to as the preparation of the present invention) characterized by being molded separately from the ingredients. In the present invention, the iodophor preparations include those that generate iodine when dissolved in water even if they do not themselves contain iodine.

In the present invention, the iodide (b) is not particularly limited as long as it is a compound that dissociates into iodide ions in an aqueous solution, and metal iodides such as alkali metal iodides (sodium iodide, potassium iodide, etc.), alkaline earth metal Examples include iodides (calcium iodide, magnesium iodide, etc.) and non-metal iodides (ammonium iodide, etc.).Among these, preferred are alkali metal iodides.

As the oxidizing agent (c), iodic acid (salt) [refers to iodic acid and/or its salt. The same expressions will be used hereinafter], bromic acid (salt), chromic acid (salt), permanganic acid (
salts), peroxyacids (salts), iodine oxides and halogenated incyanuric acids (salts).

In the oxidizing agent (c), salts include alkali metal salts (sodium salts, potassium salts, etc.), alkaline earth metal salts (
calcium salts, magnesium salts, etc.) and non-metallic salts (
ammonium salts, amine salts, etc.). Among these, preferred are alkali metal salts, and particularly preferred are sodium salts and potassium salts.

Examples of peroxyacid salts include peroxycarbonate (salt), peroxytitanium acid salt), peroxyboric acid (salt), peroxysulfuric acid (salt), and peroxyphosphoric acid (salt).

Iodine oxides include diiodine tetroxide, diiodine pentoxide, and tetraiodine nonaoxide.

Examples of the halogenated isocyanuric acid (salt) include compounds in which 1 to 3 of the 3 hydrogens of isocyanuric acid are replaced with halogens such as chlorine, iodine, or bromine, preferably chlorine, and/or salts thereof.

Among the oxidizing agents (c), preferred from the viewpoint of appearance and stability are iodate (salt), peroxy acid (salt), and halogenated incyanuric acid (salt), and particularly preferred are iodate (salt). sodium, potassium iodate, etc.) and halogenated isocyanuric acid salts) (sodium dichloroisocyanurate, trichloroisocyanuric acid, etc.).

The formulation of the present invention may contain powdered acid (d) and powdered base (e) which has the property of reacting with powdered acid (d) and foaming.

In the present invention, powdered acids (d> include powdered acids and powdered acid salts exhibiting acidity.Powdered acids include saturated dicarboxylic acids (oxalic acid, malonic acid, succinic acid, etc.), unsaturated dicarboxylic acids (maleic acid, fumaric acid, etc.), oxyacids (malic acid, tartaric acid, citric acid, etc.), and inorganic acids (boric acid, birophosphoric acid, metaphosphoric acid, phosphorous acid, etc.). Examples of salts include alkali metal hydrogen salts of inorganic acids (sodium dihydrogen phosphate, sodium hydrogen sulfate, etc.). Among (d), preferred are oxalic acid, citric acid, and alkali metal salts of hydrogen sulfate (sodium salts, etc.). It is.

Further, the powder base (e) is a salt (normal salt, acid salt, etc.) that exhibits the alkalinity of the powder and has the property of foaming upon reaction with (d). Examples of (e) include carbonates (alkali metal carbonates such as sodium carbonate, potassium carbonate, ammonium carbonate, etc.) and bicarbonates (alkali metal bicarbonates such as sodium bicarbonate, potassium bicarbonate, ammonium bicarbonate, etc.). can be given. Among (e), preferred are alkali metal hydrogen carbonate salts (such as sodium salts).

The powdered acid, powdered acid salt, and powdered base are water-soluble, and preferably have a solubility in water of 1 g or more per 100 g of water at room temperature. The melting point or decomposition point of powdered acids, powdered acid salts and powdered bases is usually 50°C or higher.

The iodine carrier (a) may be a compound commonly used for iodophors, including surfactants and non-surfactants. Surfactants include conventional surfactants such as those described in US Pat. No. 4,331,447. Specifically, nonionic, anionic, cationic and amphoteric surfactants having a (poly)oxyalkylene chain [(poly)oxyethylene, (poly)oxypropylene and/or (poly)oxybutylene chain] in the molecule are mentioned. It will be done. This nonionic surfactant is poly(3
~40 mol> Oxyalkylene (c2-C4) furkyl (ca-Cl8) ether, polyoxyethylene alkyl (c8-018) phenyl ether (polyoxyethylene octyl or nonylphenyl ether, etc.),
Examples include polyoxyethylene/polyoxypropylene block copolymers (such as Wyandotte's Pluronics) and polyoxyethylene alkylphenyl ether formalin condensates.

As the anionic surfactant, sulfate ester salts of the above-mentioned nonionic surfactants [polyoxyethylene alkyl (08-
018) Ether sulfate ester salts (alkali metal salts, ammonium salts and amine salts; hereinafter, salts are the same in anionic activators), polyoxyethylene alkyl (c8-Cl2) phenyl ether sulfate salts, etc.], phosphate esters Salt [polyoxyethylene alkyl (
c8-Cl8) ether phosphate ester salt, polyoxyethylene alkyl (c8-Cl2) phenyl ether phosphate ester salt, etc.].

As a cationic surfactant, polyoxyalkyl (c2
~C4) alkyl (012~Cl8) trimethylammonium halide (iodite, etc.), etc.
As the amphoteric surfactant, polyoxyalkyl (c2-C
4) Alkylaminoethylglycine and the like.

In addition, surfactants without (poly)oxyalkylene chains, such as anionic surfactants [alkyl (c8-Cl
8) Sulfuric acid ester salts, alkyl (c-Cl8) phosphate salts, etc.], cationic surfactants [alkyl (c-Cl8) phosphate salts, etc.], cationic surfactants [alkyl (
c8-Cl8) dimethylbenzylammonium halide, dialkyl(c8-018) dimethylammonium halide, alkyl(c8-02o) trimethylammonium halide, etc.] can also be used. These surfactants are preferably used in combination with a surfactant having a (poly)oxyalkylene chain in the molecule.

Among these surfactants, preferred are nonionic surfactants having (poly)oxyalkylene chains.

In addition, non-surfactant materials used as iodine carriers include low-molecular or high-molecular water-soluble or water-solubilizable materials. Specifically, water-soluble sugars [glucose, fructose, lactose, sucrose, xylitol, mannitol, sorbitol, dextrin, cyclodextrin,
[dextran, solubilized starch, etc.], polyvinylpyrrolidone, and polyols other than sugars [low-molecular-weight polyols such as ethylene glycol, propylene glycol, glycerin, and their alkylene oxide (ethylene oxide, etc.) adducts, such as polyethylene glycol.

The above-mentioned iodine carrier may be a mixture of two or more kinds.

In the formulation of the present invention, the content of each component in the formulation is as follows based on the weight of the formulation. That is, the iodine carrier content is usually 0.1 to 80%, preferably 5 to 50%.

The iodide content is preferably 0.01 to 20%, particularly preferably 0.1 to 10%. The amount of iodide is 0.
If the amount is less than 0.01%, sufficient iodine cannot be obtained to exhibit bactericidal efficacy when diluted with water. In addition, in order to generate enough iodine to exert a bactericidal effect during use, an amount of iodide of up to 20% is usually sufficient, but in the present invention, (b) and (c) are separately molded. Because of this, it is also possible to use iodide amounts of more than 20% (for example up to 70%, in particular up to 30%).

The oxidizing agent is usually 0.001 to 50%, preferably 0.1 to 50%.
It is 20%. Particularly preferably 0.1 to 10%.

In the case of oxidizing agents, the value is 0.00 for the same reason as in the case of iodides.
Contents below 1% and above 50% are disadvantageous.

The amount of powdered acid and powdered acid salt is usually 90% or less, preferably 10 to 70%. If it exceeds 90%, the irritation will be strong during use.

The powder base (e) is usually 50% or less, preferably 5 to 40%
%. If the amount of powder base (e) exceeds 50%, the bactericidal efficacy of iodine generated during dilution with water will decrease.

The weight ratio [(d)/(e)] of (d> and (e)) is usually 0.1 to 20, preferably 1 to 10.
．． If it is less than 1, the bactericidal power decreases during use, making it unsuitable. Moreover, if it exceeds 20, the dissolution rate becomes slow when the preparation of the present invention in the form of a tablet is dissolved in water, which is not preferable.

The preparation of the present invention may optionally contain other compounding agents (f), such as a foaming agent, a foam suppressor, and a moisture absorbent (sodium sulfate, potassium sulfate, etc.).

The preparation of the present invention comprises an iodine carrier (a), an iodide (b), an oxidizing agent (c), a powdered acid (d), and optionally a powdered base (e) which has the property of foaming when reacted with (d) [and Contains other compounding agents (f) if necessary, (b),
One of the components (c) and (d) is molded separately from the other two components; components other than (b), (c), and (d) are molded only in one of the molded products. May contain
It may also be included in both.

The molding method involves mechanically blending part or all of (a), (e) [and if necessary (f)], and adding one component of (b), (c), and (d). or 2
Ingredients are added and formed into powder, granules, or tablets, and the remaining ingredients are formed into powder, granules, or tablets. Each layer is formed into a layered tablet using a molding method, tableting method, extrusion method, etc. There are several methods. These powders, granules, tablets or layered tablets may be coated with a coating agent.

Shaped powders, granules or tablets may be packaged in separate bags; or bags divided into two compartments (1), (2) by a partition (4), as shown for example in FIG. (3) A powder containing one of the components (b), (c), and (d) in each chamber of [a bag laminated with polyethylene film, etc., with partition walls (4) formed by heat sealing]. , granules or tablets (I> and (b), (c), (d)
Powder, granule or tablet (II>) containing the remaining two ingredients can be packaged.Also, (b), (c
), (d) and granules or tablets containing the remaining two components of (b), (c), (d>) are molded separately. It is also possible to package each use in the same bag.

As a laminated tablet, for example, as shown in FIG. 2 and FIG. Laminated tablets with layer (n) containing the remaining two components of (d), or multilayer tablets with three or more layers, such as tablets containing one of the components (b), (c), and (d). (b), (c), (d) between and/or outside the layer (I> containing the remaining two components of (b), (c), and (d)). Examples include those that have a layer that does not contain them, and those that have multiple layers of (I> and /mana(II>).

The solid iodophor preparation of the present invention dissolves rapidly when added to water.

When the preparation of the present invention is dissolved in water, the effective iodine content generated is not particularly limited, but based on the weight of the preparation, it is usually o, oi to 45%, preferably 0.1 to 20%, particularly preferably 0. .2 to 10%.

When the preparation of the present invention is used, the effective iodine concentration is usually several ppm.
It is used by diluting it with water to a concentration of 1 to 150 ppm, but it can also be used by dissolving one auxiliary agent in 11 parts of water.

[Examples] The present invention will be further described below with reference to Examples, but the present invention is not limited thereto.

The raw materials used in the examples are as follows.

A1: Polyethylene glycol (molecule 5L20,000
) A2: Polyoxyethylene nonylphenyl ether (
n: 20) A3: Polyvinylpyrrolidone (k: 20) A4: Dextran 40 B1: Sodium iodide C1: Sodium iodate C2 Sodium dichloroin cyanurate Old: Oxalic acid D2: Sodium hydrogen sulfate 03: Citric acid El: Carbonic acid Sodium hydrogen Fl: Anhydrous sodium sulfate Examples 1 to 8 Component (1) and component (2) having the composition (wt%) shown in Table 1 were separately molded to form a laminated tablet as shown in Figures 2 and 3. A formulation of the present invention was prepared consisting of:

Table 1 The effective yield and external Fyi*2 and dissolution time*3 of the obtained preparations were measured at the time of preparation (■) and after 6 cycles at room temperature (■). The results are shown in Table 2.

(Note) *1: Means iodine that can be titrated with sodium periosulfate in the aqueous solution of the preparation.

*2: ◎ represents a white to slightly yellow tablet.

*3: Time (minutes) required to dissolve 1 g (Ig) of the preparation in 100 ml of water.

Table 2 [Effects of the Invention] The preparation of the present invention does not require any complicated steps as in the conventional manufacturing process, and is simple and requires only mechanical blending. That is,
Conventional ones (for example, Japanese Patent Application Laid-Open No. 50-35318)
was manufactured using a complicated process of first preparing a polyvinylpyrrolidone-iodide solid solution by drying a solution containing polyvinylpyrrolidone and iodide, and then mechanically blending it with elemental iodine. can be easily manufactured.

Furthermore, the stability of the formulation is excellent. Furthermore, when the tablet preparation is dissolved in water, it dissolves quickly and generates iodine, so it has excellent bactericidal activity.

Moreover, the formulation of the present invention contains iodide (b) and oxidizing agent (c).
), the stability of the formulation, especially the appearance stability, is significantly improved compared to those molded at the same time, and the appearance of the formulation is less likely to be colored or have iodine spots when administered orally. It is stable for a long period of time, and it is also possible to increase the effective iodine concentration.

Because it exhibits the above-mentioned effects, the preparation of the present invention can be used in the fields of medicine, dairy farming, food processing, environmental hygiene, etc. to disinfect walls and floors of public buildings, disinfect and clean storage buildings and storage bodies, and disinfect adjustment equipment and equipment. It is used to sterilize and disinfect the skin of animals and humans.

[Brief explanation of the drawing]

FIG. 1 is a front view of a preparation packaged in a bag separated into two compartments, and FIGS. 2 and 3 are a cross-sectional view and a perspective view, respectively, of a laminated tablet. In the figure, ■ indicates a powder or granules containing iodide or an iodide-containing layer, ■ indicates a powder or granules containing an oxidizing agent or an oxidizing agent-containing layer, (1)
and (2) a chamber containing an iodide-containing powder or granules and an oxidizing agent-containing powder or granules, respectively; (3)
represents a bag, and (4) represents a partition wall. Fig. 1 Fig. 2 Fig. 3 ■ Procedures 1n Yoshi, Director General of the Ministry of Justice and Correction 1) Takeshi Moon 1, Indication of the case Patent Application No. 248507 of 1988 2, Name of the invention Solid iodophor preparation 3, Amendment (1) Define the scope of claims on pages 1 to 4 of the specification as “1.
It contains an iodine carrier (a), an iodide (b), an oxidizing agent (c), a powdered acid (d), and optionally a powdered base (e) that has the property of reacting with (d) to form foam, and ( b), (
A solid iodophor preparation characterized in that one of c) and (d) is molded separately from the other two components. Spontaneous 5, number of claims increased by amendment 3, iodine carrier (a), iodide (b), oxidizing agent (c)
, containing a powdered acid (d) and a powdered base [e) that has the property of foaming when reacted with (d), and characterized in that (b) and (c) are molded separately. Solid iodophor preparation. 4. A layer containing one or two components behind (b), (c), (d) and the other (b), (c), (
The formulation according to any one of claims 1 to 3, which is a laminated tablet with a layer containing the component of d). 5. Powders, granules or tablets containing one or two ingredients of (b), (c) and (d) and other (b)
), CG), and a powder, granule, or tablet containing the ingredients of (d). The formulation described in any of the above. ” he corrected. (2) Ibid., page 4, line 18 to page 5, line 3 [That is, the present invention includes; iodine carrier (a), iodide (b),
It contains an oxidizing agent (c), a powdered acid (d), and optionally a powdered base (e) that has the property of foaming by reacting with (d), and among (b), (c), and (d). This is a solid iodophor preparation (hereinafter referred to as the preparation of the present invention) characterized in that one component is molded separately from the other two components. "In other words, the present invention: iodine carrier (a), iodide (b)
), oxidizing agent (c), powder m(d) and optionally (d
) containing a powdered base (e) that has the property of foaming by reacting with the base, and one of the components (b), (c), and (d) is molded separately from the other two components. Characteristic solid iodophor preparation (hereinafter referred to as the preparation of the present invention) and an iodine carrier (a), an iodide (b), an oxidizing agent (c), a powdered acid (d) and optionally (d). Contains a powdered base (e) with foaming properties, (b), (c
) A solid iodophor preparation (hereinafter referred to as the preparation of the present invention) characterized in that the same component and component (d) are molded separately, and an iodine carrier (a), an iodide (b), an oxidizing agent (c ), contains a powdered acid (d) and a powdered base (e) which has the property of foaming by reacting with (d), and contains (b) and (
c) is a solid iodophor preparation (hereinafter referred to as the preparation of the present invention) characterized in that it is separately molded. ” is corrected.

Claims (1)

[Claims] 1. Iodine carrier (a), iodide (b), oxidizing agent (c)
(b)
, (c), and (d) are molded separately from the other two components. 2. Iodine carrier (a), iodide (b), oxidizing agent (c)
, containing a powdered acid (d) and a powdered base (e) that has the property of foaming when reacting with (d), and characterized in that (b) and (c) are molded separately. Solid iodophor preparation. 3. (c) is a group consisting of iodic acid (salt), bromic acid (salt), chromic acid (salt), permanganic acid (salt), peroxyacid (salt), iodine oxide, and halogenated isocyanuric acid (salt) The formulation according to claim 1 or 2, which is a compound selected from: 4. The content of (b) is 0.01 to 0.01 based on the weight of the preparation
4. A formulation according to any one of claims 1 to 3, wherein the amount is 20%. 5, the content of (b) is 20-70 based on the weight of the preparation
The formulation according to any one of claims 1 to 3, which is %. 6, the content of (c) is 0.001 based on the weight of the preparation
-50%. 7, (d) is a saturated dicarboxylic acid, an unsaturated dicarboxylic acid,
The formulation according to any one of claims 1 to 6, which is a compound selected from the group consisting of oxyacids, inorganic acids, and acidic salts of inorganic acids. 8. The formulation according to any one of claims 1 to 7, wherein the content of (d) is 90% or less based on the weight of the formulation. 9. The formulation according to any one of claims 1 to 8, wherein (e) is a carbonate and/or a bicarbonate. 10. The formulation according to any one of claims 1 to 9, wherein the content of (e) is 50% or less based on the weight of the formulation. 11. The formulation according to any one of claims 1 to 10, wherein (a) is a compound selected from the group consisting of a surfactant, a saccharide, polyvinylpyrrolidone, and a polyol other than saccharides. 12. The content of (a) is 0.1 to 0.1 based on the weight of the preparation.
12. A formulation according to any one of claims 1 to 11, which is 80%. 13, one or two components of (b), (c), (d)
Component-containing layer and other layers (b), (c), and (d)
Claim 1: The tablet is a laminated tablet with a layer containing the following ingredients:
13. The formulation according to any one of 12 to 12. 14. The formulation according to any one of claims 1 to 12, which is a laminated tablet comprising a layer containing (b) and a layer containing (c). 15, one or two components of (b), (c), (d)
Powders, granules or tablets containing ingredients and other (
The formulation according to any one of claims 1 to 12, comprising a powder, granule, or tablet containing the components b), (c), and (d). 16, a powder, granule or tablet containing (b);
13. The formulation according to any one of claims 1 to 12, comprising a powder, granule or tablet containing c).